Skip to main content

Gonal-f RFF Redi-ject Disease Interactions

There are 3 disease interactions with Gonal-f RFF Redi-ject (follicle stimulating hormone).

Major

Follicle stimulating hormone (applies to Gonal-f RFF Redi-ject) adrenal dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Adrenal Insufficiency, Hyperadrenocorticism

The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled adrenal dysfunction. Uncontrolled adrenal dysfunction may involve the pituitary gland and be associated with a tumor or other dysfunction. Administration of FSH may exacerbate the condition.

References (4)
  1. "Product Information. Fertinex (urofollitropin)." Serono Laboratories Inc
  2. (2002) "Product Information. Follistim (follicle stimulating hormone)." Organon
  3. (2002) "Product Information. Gonal-F (follicle stimulating hormone)." Serono Laboratories Inc
  4. (2003) "Product Information. Bravelle (urofollitropin)." Ferring Pharmaceuticals Inc
Major

Follicle stimulating hormone (applies to Gonal-f RFF Redi-ject) thyroid dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Hypothyroidism, Hyperthyroidism

The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled thyroid dysfunction. FSH is composed of both an alpha and beta subunit. The amino acid sequence of the alpha subunit of FSH is identical to that of TSH. Therefore, FSH may have weak TSH receptor- binding and activation.

References (4)
  1. "Product Information. Fertinex (urofollitropin)." Serono Laboratories Inc
  2. (2002) "Product Information. Follistim (follicle stimulating hormone)." Organon
  3. (2002) "Product Information. Gonal-F (follicle stimulating hormone)." Serono Laboratories Inc
  4. (2003) "Product Information. Bravelle (urofollitropin)." Ferring Pharmaceuticals Inc
Major

Follicle stimulating hormone (applies to Gonal-f RFF Redi-ject) tumors

Major Potential Hazard, High plausibility. Applicable conditions: Neoplasia -- Estrogen Dependent

The use of follicle stimulating hormone is contraindicated in patients with sex hormone-dependent tumors of the reproductive tract and accessory organs (ovary, breast, uterus) and in patients with pituitary tumors. FSH is required for normal sex hormone production, which may be detrimental in these patients. Patients in later reproductive life have a greater predisposition to endometrial carcinoma.

References (4)
  1. "Product Information. Fertinex (urofollitropin)." Serono Laboratories Inc
  2. (2002) "Product Information. Follistim (follicle stimulating hormone)." Organon
  3. (2002) "Product Information. Gonal-F (follicle stimulating hormone)." Serono Laboratories Inc
  4. (2003) "Product Information. Bravelle (urofollitropin)." Ferring Pharmaceuticals Inc

Switch to consumer interaction data

Gonal-f RFF Redi-ject drug interactions

There is 1 drug interaction with Gonal-f RFF Redi-ject (follicle stimulating hormone).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer